
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

Theodore Wagener, PhD, discusses psychedelics beyond depression in cancer, including neuropathy and chemo brain, and why he expects cancer centers to adopt them.

Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer.